Evgen Pharma PLC - clinical stage drug development company - Notes that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by some variants of coronavirus. Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex.
"We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021," says Chief Executive Huw Jones.
Current stock price: 8.28 pence, up 1.0% on Wednesday
Year-to-date change: down 19%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.